Mastering Urine Microscopy

On-demand Webinar: Microscopy in urinalysis.

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

Europeiska läkemedelsaktier faller inför Trumps tullbesked

Flera bolag inom den europeiska läkemedelssektorn sjunker på börsen inför kvällens tullbesked från USA.

He is heading a new company for the development of Coegin’s cancer drug

The biotechnology company Coegin Pharma places the development of its drug candidate AVX420 in a newly formed company, Avexxin Oncology, based in Norway, and Jo...

Conference on Alzheimer’s reveals several advances in the field

In Gothenburg, Sweden, researchers and pharmaceutical companies from all over the world gathered to discuss one specific issue – neurological diseases. Life Sci...

Anna Törner: To kill your darlings

Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of excit...

From the sea of Åland to a self-test for lithium

Four years ago, a meeting on the sea of Åland resulted in the development of a self-test for lithium levels in the blood. The hopes are that the test will be av...

“Photon counting in computed tomography is the holy grail”

Erik Fredenberg, a researcher in physics at KTH and GE, is working to implement photon-counting CT in clinics. To shorten lead times and reduce the radiation do...

Uncertainty about the government’s life science work

The government’s national coordinator for life science, Jenni Nordborg, left her position almost four months ago. No one has yet succeeded her, and now question...

Misslyckande för BMS i sen studie om hjärtläkemedel

Läkemedelsjätten Bristol Myers Squibbs läkemedel mot en typ av hjärtsjukdom misslyckades i en sen klinisk studie. Det svaga utfallet ökar kraven på positiva utf...

High-performance Slide Scanner for Fluorescence, Brightfield and Polarization

ZEISS Axioscan 7 combines high speed digitization and outstanding image quality.

Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”

The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.

Mercodia AB

Introduction of ZEISS Imaging Systems for Super-Resolution

Webinar recording about the ZEISS Lattice SIM technology.

Roche överväger stoppa USA-satsning om Trump fullföljer läkemedelsplan

President Donald Trumps försök att pressa internationella företag att investera mer i USA, bland annat genom kontroversiella tullar kan få motsatt effekt. Nu öv...

Improved processes and more

Discover the full potential and benefits.

“Unfortunately, we are not strong when it comes to conducting clinical trials”

The number of company-initiated clinical trials conducted in Sweden has been declining in recent years. In mid-March, a government inquiry was presented that ai...

The route to vaccines for everyone: “We did not just sit around and wait”

The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a propos...

Automate E2E Image Analysis Pipelines

ZEISS arivis Pro - Your End-to-End Scientific Image Analysis Software.

Viktor Hrvota dubblar vd-skapet – tar över Umecrine Cognition

Umecrine Cognition har utsett Viktor Drvota till ny vd efter avgående Anders Karlsson.

Marie Gårdmark: Potential step change – EU regulators get to play with data

A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward...

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leavi...